Clinical Trials Logo

Filter by:
NCT ID: NCT04066660 Suspended - Clinical trials for Advanced Hepatocellular Carcinoma

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

A randomized, double-blind, controlled trial was conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da. as a supplemental therapy in patients with metastatic colorectal cancer. The previous study results demonstrate the advantages of Oligo-Fucoidan in improving the disease control rate. The previous study might provide insights into the development of cancer treatments, particularly in the combination of natural or herbal products with chemotarget agents.

NCT ID: NCT04064658 Suspended - Moyamoya Disease Clinical Trials

Effects of Remote Ischemic Pre-Conditioning in Moyamoya Disease Patients

RIME
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

In the present study, investigators evaluated whether RIPC reduce the major neurological complications in adult moyamoya disease patients undergoing encephaloduroarteriosynangiosis (EDAS).

NCT ID: NCT04053062 Suspended - Clinical trials for Castrate-Resistant Prostate Cancer

LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Start date: July 16, 2020
Phase: Phase 1
Study type: Interventional

This is a single center, single arm Phase I study to establish the safety and efficacy of intravenously administered lentivirally transduced LIGHT-PSMA-specific CAR modified autologous T cells (PSMA-CART cells) in patients with CRPC.

NCT ID: NCT03990974 Suspended - Clinical trials for Hepatocellular Carcinoma

Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection

HCC
Start date: September 2020
Phase: Phase 3
Study type: Interventional

This trial is a multi-center, double-blinded, randomized (1:1) clinical trial. The aim is to compare the postoperative infection rate between the 3 days postoperative AMP group and the placebo group in HCC patients undergoing hepatectomy.

NCT ID: NCT03973710 Suspended - Hypertension Clinical Trials

Effect of Probiotics on Blood Pressure Management

Start date: June 3, 2022
Phase: N/A
Study type: Interventional

Dysbiosis of gut microbiota has been reported to be involved in the development and progression of hypertension in both humans and animal models. Probiotics have been reported to have ameliorative effects in murine models. However, whether probiotics could help alleviate hypertension in adults remain obscure.

NCT ID: NCT03958929 Suspended - Glaucoma Clinical Trials

Impact of an Educational Video on Satisfaction After Glaucoma Surgery

Start date: October 10, 2023
Phase: N/A
Study type: Interventional

Overall Objective: This study will assess whether an educational video is effective in increasing patient satisfaction with glaucoma surgery. 1. Investigate the impact of educational interventions on glaucoma patients' surgical satisfaction. 2. Investigate the post-operative satisfaction of rural glaucoma patients in county hospitals 3. Investigate the difference in postoperative satisfaction between urban and rural glaucoma patients in urban hospitals 4. Investigate other factors that influence postoperative glaucoma satisfaction.

NCT ID: NCT03945786 Suspended - Clinical trials for Endometrial Carcinoma

Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial Carcinoma

Start date: June 3, 2019
Phase:
Study type: Observational

Endometrial carcinoma (EC) is one of the most common gynecologic malignancy in China. EC is staged surgically according to the International Federation of Gynecology and Obstetrics (FIGO) system, including depth of myometrial invasion, cervical invasion, and the presence of lymph node metastases. The benefit of lymph node resection on the prognosis of low-risk EC patients is not definite. An accurate staging method preoperative is needed.The purpose of this study is to evaluate the effect of simultaneous hybrid PET/MRI in EC preoperative staging.

NCT ID: NCT03932253 Suspended - Melanoma Clinical Trials

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Start date: March 21, 2019
Phase: Phase 1
Study type: Interventional

Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas. Acquisition of a functional mutation in NRAS results in activation of the Ras / Raf / MEK / ERK signaling pathway leading to unconstrained cell growth and cell transformation. NRAS mutation status was identified as an independent poor prognostic factor in stage IV melanoma. No drug was approved to treat melanoma patients with NRAS mutation or amplification until now. FCN-159, an oral and potent MEK1/2 inhibitor, has more than 10 folds higher selectivity against activated MEK1 and MEK2 compared with trametinib, and has demonstrated significant antitumor growth inhibition in two patient-derived xenograft (PDX) models with NRAS mutation. Approximately 10%-15% of melanomas is reported to be NF1-mutant. NF1 gene is located in chromosome 17 q11.2 and encodes neurofibromin 1. Neurofibromin 1 is a RAS-specific GTP enzyme-activated protein that converts RAS from the active guanosine triphosphate (GTP) binding state to the inactivated guanosine diphosphate (GDP) binding state and acts as a negative regulatory factor for RAS and its downstream MAPK and PI3K-Akt pathways. Recent treatments of NF1 mutation focus on the downstream of the MAPK pathway, such as MEK kinase. Blocking the MEK kinase can reduce neurofibroma in mice with NF1 mutation and prolong the survival time of mice with malignant peripheral nerve sheath tumor (MPNST) xenograft. In the NF1 mutant monocytic leukemia mouse model, the use of MEK inhibitors can improve mouse survival rate. This is the first in human study to evaluate the safety and anti-tumor activity in patients.

NCT ID: NCT03906565 Suspended - Clinical trials for Advanced or Metastatic CRC

Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer

Start date: April 12, 2019
Phase: Phase 2
Study type: Interventional

To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic colorectal cancer (CRC) as a phase II trial

NCT ID: NCT03843918 Suspended - Clinical trials for Prostate Cancer Metastatic

A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

Start date: April 5, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multicenter phase I/II study of the treatment of patients with metastatic prostate cancer. The objective of Phase I part is to study the safety and tolerability of LAE001 monotherapy in patients with metastatic castration-resistant prostate cancer, and determine the maximum tolerated dose (MTD) as well as the recommended phase II dose (RP2D) of the drug, the Phase II part is to assess the efficacy of LAE001 based on PSA in the treatment of patients with metastatic castration-resistant prostate cancer.